A Patient's Perspective

Jenny Bogle—Ovarian cancer patient London, England.
Jenny Bogle—Ovarian cancer patient London, England.

Contact Us

"I recommend using CANCER PANELS for any patient who has a very complex illness and faces important questions on the best next steps in their options and treatment."

John Hutchins—Founder
PinnacleCare, Private Health Advisory

Contact us today in
strictest confidence
CALL 703-919-9945 (USA)

The panel greatly improves ability to obtain the most appropriate treatment at an EARLIER stage.

The panel can be set up within two to five weeks. Panel members meet in person, usually in an East Coast city in the United States, such as New York or Washington, to review and discuss the cancer patient's case. The panel typically lasts about three hours. The panel first reviews the cancer patient’s medical history, radiological imaging scans, pathology and results of any molecular tests. Following the review, the panel discusses various treatment and research approaches, both conventional and novel, advanced chemotherapeutic drugs and biologics as well as accessible clinical trials that are available to the treating physician. After the panel, the cancer patient's treating physician is advised of the panel's consensus treatment recommendation. The panel reconvenes again at a later date via teleconference to review the cancer patient's progress and other developments and, at that time, makes additional recommendations that may be necessary. 

cancerpanelsbodyimage.jpg

The panel is regularly chaired by Dr. David Sidransky, consultant to the Company. He is a Professor of Otolaryngology, Head and Neck Surgery, Oncology, Pathology, Urology, Cellular and Molecular Medicine and the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Sidransky is considered to be one of the world's leading cancer specialists and the premier investigator in the field of molecular diagnostics, targeted therapies and individualized patient treatments. He was profiled in TIME magazine as one of the top physicians and scientists in America and is one of the five most highly cited oncology researchers in clinical and medical journals in the world during the past decade.

More

The in-person professional deliberations held in a private forum allow for not only consensus treatment options among panel members, but also for the opportunity to share their ideas as well as current practices and latest research that stimulate the transfer of knowledge among colleagues. When panelists return to their own practices, the information they acquired trickles down quickly to multiple cancer centers, hospitals and academic institutions for likely use in the care of other patients with similar diagnoses. Consequently, in addition to having their own innovative treatments identified, individuals diagnosed with cancer that hold these panels may have the opportunity to help those who are less privileged to benefit from lifesaving options that would otherwise never have become known to them.

We encourage cancer patients and their families/friends to obtain as many opinions as they feel necessary. However, there are many leading cancer experts and prominent cancer institutions for a given disease. Furthermore, leading experts may provide conflicting and divergent advice regarding the specific recommendations for an individual’s cancer treatment. 

Additionally, this process of gathering opinions from various places is quite time-consuming and TIME IS THE MOST PRECIOUS COMMODITY WHEN IT COMES TO FIGHTING ADVANCING CANCER.

The real advantage, and essence, of our panel, is that it bypasses this time-consuming process and quickly gathers renowned experts in a round-table in-person forum where options are fully debated until the panel provides the cancer patient’s treating physician with a consensus treatment recommendation. The panel thus maximizes options available to the cancer patient's physician and greatly improves their ability to obtain the most appropriate treatment at an EARLIER stage.